Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
MedImmune reports revenues of $1.2 billion
February 27th, 2006
MedImmune, Inc. (MEDI) announced that total revenues for 2005 were $1.2 billion, representing a 9% increase over $1.1 billion in revenues for 2004.
For the 2005 fourth quarter, MedImmune's total revenues increased 6% to $492 million from $466 million in the 2004 fourth quarter.
David M. Mott, president and chief executive officer said, "We continued to invest aggressively in building our future with research and development (R&D) expenditures reaching 31% of product sales as we successfully completed multiple phase 3 trials, filed three investigational new drug applications, and added 11 new targets to our portfolio. On the revenue side,...
Source: Pharma Business Week (2006-02-27)
|
